• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At MapLight Therapeutics (MPLT) Valuation After Its Sharp Recent Share Price Surge

    Simply Wall St·04/19/2026 00:18:46
    語音播報

    MapLight Therapeutics (MPLT) has drawn attention after a sharp share price move over the past month, with the stock closing at US$30.05 and a market value around US$1.24b, inviting closer scrutiny from biotech investors.

    See our latest analysis for MapLight Therapeutics.

    The recent 76.6% 30 day share price return, and 79.2% year to date share price return, point to strong short term momentum that contrasts with MapLight Therapeutics’ early stage fundamentals and lack of reported revenue so far.

    If you are looking for other high growth ideas in related areas, it can be useful to scan the broader market using tools such as the 35 healthcare AI stocks

    With shares already up around 77% over 30 days and trading close to the average analyst price target of US$32.67, the key question is whether MapLight still offers upside or if the market is already pricing in future growth.

    Preferred Price to Book Multiple of 2.9x: Is it justified?

    MapLight Therapeutics trades on a P/B of 2.9x at a last close of $30.05, which screens as expensive versus the broader US biotechs industry but looks low against its immediate peer set.

    The P/B multiple compares the company’s market value with its book value. This can be a common reference point for early stage biopharma names that have no revenue and are loss making. With MapLight reporting $0 in revenue and a net loss of $161.152m, investors are effectively paying for its clinical pipeline, intellectual property and balance sheet rather than current earnings.

    Compared with the US biotechs industry average P/B of 2.4x, the 2.9x multiple suggests the market is assigning a higher valuation than the wider group. This indicates that stronger expectations are already embedded in the share price. However, relative to a much higher peer average P/B of 52.6x, MapLight’s multiple sits at a sizeable discount. This highlights how different reference groups can paint very different pictures of value and sentiment.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price to book ratio of 2.9x (ABOUT RIGHT)

    However, there are still clear pressure points, including the current US$161.152m net loss and the risk that clinical-stage assets fail to progress as expected.

    Find out about the key risks to this MapLight Therapeutics narrative.

    Next Steps

    If this sharp move and mixed signals leave you unsure, do not wait on others to decide for you. Review the 4 important warning signs.

    Looking for more investment ideas?

    If MapLight has caught your eye, do not stop there. Widen your watchlist with other focused sets of companies that might fit your style and risk tolerance.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.